Harga yang bagus  on line

rincian produk

Created with Pixso. Rumah Created with Pixso. Produk Created with Pixso.
Obat Kanker Payudara
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Nama Merek: Boehringer Ingelheim
Nomor Model: Tablet Berlapis Film 18mg
MOQ: 1 buah
harga: Please contact a specialist WhatsApp:55342706
Waktu Pengiriman: Bisa dinegosiasikan
Ketentuan Pembayaran: Western Union, MoneyGram, T/T.
Informasi Rinci
Tempat asal:
Amerika Serikat
Sertifikasi:
FDA NDA 218764
Spesifikasi:
18mg*60 tablet/kotak
Indikasi:
Fibrosis paru idiopatik, fibrosis paru progresif
Target:
PDE4B
Nama Produk:
Nerandomilast
Menyarankan:
Silakan ikuti saran dokter
Penyimpanan:
Simpan pada suhu 20°C hingga 25°C, memungkinkan perubahan suhu sekitar antara 15°C dan 30°C, jauhkan
Suhu Penyimpanan:
20°C hingga 25°C
Kisaran suhu sekitar:
15°C hingga 30°C
Bentuk Dosis:
Tablet berlapis film
Kekuatan tablet:
18mg
Ukuran Paket:
60 tablet/kotak
Enzim sasaran:
PDE4B
Kemasan rincian:
Bisa dinegosiasikan
Menyediakan kemampuan:
Bisa dinegosiasikan
Menyoroti:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Deskripsi Produk
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.